Vero cell culture-derived pandemic influenza vaccines: Preclinical and clinical development

Expert Review of Vaccines

Volumn 12, Issue 4, 2013, Pages 395-413

  Barrett, P Noel ^a   Portsmouth, Daniel ^a   Ehrlich, Hartmut J ^a  

^a BAXTER BIOSCIENCE   (Austria)

Author keywords

cell culture; clinical trial; H1N1pdm09; H5N1; H9N2; influenza; pandemic; vaccine; Vero; whole virus

Indexed keywords

INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; VACCINIA VACCINE;

ABSENTEEISM; ANOREXIA; ANTIBODY RESPONSE; ANTIBODY TITER; BIOSAFETY; CELLULAR IMMUNITY; CHRONIC PATIENT; CLADISTICS; CRYING; DENGUE; DROWSINESS; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ENDOCYTOSIS; FATIGUE; FEVER; GENETIC REASSORTMENT; HEADACHE; HEMAGGLUTINATION INHIBITION; HEMOLYSIS; HIGH RISK POPULATION; HUMAN; IMMUNOGENICITY; INFLUENZA A; INFLUENZA VIRUS A H5N1; INJECTION SITE PAIN; INJECTION SITE SWELLING; IRRITABILITY; LONG TERM MEMORY; MALAISE; MEMORY CELL; MORTALITY; MYALGIA; NONHUMAN; PANDEMIC; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PINOCYTOSIS; PRIMARY IMMUNE RESPONSE; PRIORITY JOURNAL; PROGENY; PROTEIN ANALYSIS; REVIEW; SEASONAL INFLUENZA; SEROCONVERSION; SHIVERING; SIDE EFFECT; SKIN INDURATION; SLEEP DISORDER; T LYMPHOCYTE ACTIVATION; VACCINATION; VACCINE PRODUCTION; VACCINIA VIRUS; VERO CELL; VIRUS RELEASE; VOMITING;

ANIMALS; CELL CULTURE TECHNIQUES; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; HUMANS; INFLUENZA A VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; TECHNOLOGY, PHARMACEUTICAL; VERO CELLS;

EID: 84875964790     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.13.21     Document Type: Review

References (91)

1. Watanabe Y, Ibrahim MS, Suzuki Y, Ikuta K. The changing nature of avian influenza A virus (H5N1). Trends Microbiol. 20(1), 11-20 (2012).
2. Herfst S, Schrauwen EJ, Linster M et al. Airborne transmission of influenza A/ H5N1 virus between ferrets. Science 336(6088), 1534-1541 (2012).
3. Imai M, Watanabe T, Hatta M et al. Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/ H1N1 virus in ferrets. Nature 486(7403), 420-428 (2012).
4. Imai M, Kawaoka Y. The role of receptor binding specificity in interspecies transmission of influenza viruses. Curr. Opin. Virol. 2(2), 160-167 (2012).
5. Watanabe Y, Ibrahim MS, Ellakany HF et al. Acquisition of human-type receptor binding specificity by new H5N1 influenza virus sublineages during their emergence in birds in Egypt. PLoS Pathog. 7(5), e1002068 (2011).
6. Broberg E, Nicoll A, Amato-Gauci A. Seroprevalence to influenza A(H1N1) 2009 virus -where are we? Clin. Vaccine Immunol. 18(8), 1205-1212 (2011).
7. Shrestha SS, Swerdlow DL, Borse RH et al. Estimating the burden of 2009 pandemic influenza A (H1N1) in the United States (April 2009-April 2010). Clin. Infect. Dis. 52(Suppl. 1), S75-S82 (2011).
8. Dawood FS, Iuliano AD, Reed C et al. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infect. Dis. 12(9), 687-695 (2012).
9. Ferguson NM, Cummings DA, Fraser C, Cajka JC, Cooley PC, Burke DS. Strategies for mitigating an influenza pandemic. Nature 442(7101), 448-452 (2006). (Pubitemid 44264793)
10. Perdue ML, Arnold F, Li S et al. The future of cell culture-based influenza vaccine production. Expert Rev. Vaccines 10(8), 1183-1194 (2011).
11. Jennings LC, Monto AS, Chan PK, Szucs TD, Nicholson KG. Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans. Lancet Infect. Dis. 8(10), 650-658 (2008).
12. Palache B, Krause R. Progress with human H5N1 vaccines: a perspective from industry. Expert Rev. Vaccines 8(4), 391-400 (2009).
13. Rebmann T, Zelicoff A. Vaccination against influenza: role and limitations in pandemic intervention plans. Expert Rev. Vaccines 11(8), 1009-1019 (2012).
14. Leroux-Roels I, Leroux-Roels G. Current status and progress of prepandemic and pandemic influenza vaccine development. Expert Rev. Vaccines 8(4), 401-423 (2009).
15. Committee for Proprietary Medicinal Products. Note for Guidance on Harmonisation of Requirements for Influenza Vaccines. Report No.: CPMP/ BWP/214/96. European Agency for the Evaluation of Medicinal Products (EMEA), London, UK (1997).
16. Johansson BE, Cox MM. Influenza viral neuraminidase: the forgotten antigen. Expert Rev. Vaccines 10(12), 1683-1695 (2011).
17. Marcelin G, Bland HM, Negovetich NJ et al. Inactivated seasonal influenza vaccines increase serum antibodies to the neuraminidase of pandemic influenza A(H1N1) 2009 virus in an age-dependent manner. J. Infect. Dis. 202(11), 1634-1638 (2010).
18. Marcelin G, DuBois R, Rubrum A, Russell CJ, McElhaney JE, Webby RJ. A contributing role for anti-neuraminidase antibodies on immunity to pandemic H1N1 2009 influenza A virus. PLoS ONE 6(10), e26335 (2011).
19. Doherty PC, Turner SJ, Webby RG, Thomas PG. Influenza and the challenge for immunology. Nat. Immunol. 7(5), 449-455 (2006).
20. McKinstry KK, Strutt TM, Swain SL. Hallmarks of CD4 T cell immunity against influenza. J. Intern. Med. 269(5), 507-518 (2011).
21. McElhaney JE, Xie D, Hager WD et al. T cell responses are better correlates of vaccine protection in the elderly. J. Immunol. 176(10), 6333-6339 (2006).
22. Barrett PN, Mundt W, Kistner O, Howard MK. Vero cell platform in vaccine production: moving towards cell culturebased viral vaccines. Expert Rev. Vaccines 8(5), 607-618 (2009).
23. Barrett PN, Portsmouth D, Ehrlich HJ. Developing cell culture-derived pandemic vaccines. Curr. Opin. Mol. Ther. 12(1), 21-30 (2010).
24. Hess RD, Weber F, Watson K, Schmitt S. Regulatory, biosafety and safety challenges for novel cells as substrates for human vaccines. Vaccine 30(17), 2715-2727 (2012).
25. Reynales H, Astudillo P, de Valliere S et al A prospective observational safety study on MF59((R)) adjuvanted cell culture-derived vaccine, Celtura((R)) during the A/H1N1 (2009) influenza pandemic. Vaccine 30(45), 6436-6443 (2012).
26. Kistner O, Barrett PN, Mundt W et al. Development of a mammalian cell (Vero) derived candidate influenza virus vaccine. Vaccine 16(9-10), 960-968 (1998). (Pubitemid 28276008)
27. Kistner O, Howard MK, Spruth M et al. Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Vaccine 25(32), 6028-6036 (2007). (Pubitemid 47077543)
28. Howard MK, Kistner O, Barrett PN. Pre-clinical development of cell culture (Vero)-derived H5N1 pandemic vaccines. Biol. Chem. 389(5), 569-577 (2008). (Pubitemid 351874194)
29. Howard MK, Sabarth N, Savidis-Dacho H et al. H5N1 whole-virus vaccine induces neutralizing antibodies in humans which are protective in a mouse passive transfer model. PLoS ONE 6(8), e23791 (2011).
30. Sabarth N, Howard MK, Savidis-Dacho H, van Maurik A, Barrett PN, Kistner O. Comparison of single, homologous prime-boost and heterologous prime-boost immunization strategies against H5N1 influenza virus in a mouse challenge model. Vaccine 28(3), 650-656 (2010)
31. Sabarth N, Savidis-Dacho H, Schwendinger MG et al. A cell culture-derived whole-virus H5N1 vaccine induces long-lasting cross-clade protective immunity in mice which is augmented by a homologous or heterologous booster vaccination. Vaccine 30(37), 5533-5540 (2012).
32. van Maurik A, Sabarth N, Dacho HS et al. Seasonal influenza vaccine elicits heterosubtypic immunity against H5N1 that can be further boosted by H5N1 vaccination. Vaccine 28(7), 1778-1785 (2010).
33. Geeraedts F, Bungener L, Pool J, ter Veer W, Wilschut J, Huckriede A. Whole inactivated virus influenza vaccine is superior to subunit vaccine in inducing immune responses and secretion of proinflammatory cytokines by DCs. Influenza Other Respi. Viruses 2(2), 41-51 (2008).
34. Hagenaars N, Mastrobattista E, Glansbeek H et al. Head-to-head comparison of four nonadjuvanted inactivated cell culturederived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model. Vaccine 26(51), 6555-6563 (2008).
35. Geeraedts F, Goutagny N, Hornung V et al. Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signalling. PLoS Pathog. 4(8), e1000138 (2008).
36. Nicholson KG, Tyrrell DA, Harrison P et al. Clinical studies of monovalent inactivated whole virus and subunit A/ USSR/77 (H1N1) vaccine: serological responses and clinical reactions. J. Biol. Stand. 7(2), 123-136 (1979). (Pubitemid 9149059)
37. Ehrlich HJ, Müller M, Oh HM et al.; Baxter H5N1 Pandemic Influenza Vaccine Clinical Study Team. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N. Engl. J. Med. 358(24), 2573-2584 (2008). (Pubitemid 351831358)
38. Leroux-Roels I, Borkowski A, Vanwolleghem T et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370(9587), 580-589 (2007). (Pubitemid 47247854)
39. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N. Engl. J. Med. 354(13), 1343-1351 (2006).
40. Bresson JL, Perronne C, Launay O et al. Safety and immunogenicity of an inactivated split-virion influenza A/ Vietnam/1194/2004 (H5N1) vaccine: Phase I randomised trial. Lancet 367(9523), 1657-1664 (2006). (Pubitemid 43744370)
41. Treanor JJ, Wilkinson BE, Masseoud F et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 19(13-14), 1732-1737 (2001). (Pubitemid 32175735)
42. Ehrlich HJ, Müller M, Fritsch S et al. A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses. J. Infect. Dis. 200(7), 1113-1118 (2009).
43. Tambyah PA, Wilder-Smith A, Pavlova BG et al. Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccine. Vaccine 30(2), 329-335 (2012).
44. van der Velden MV, Aichinger G, Pöllabauer EM et al. Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces longlasting cross-reactive memory immune response: homologous or heterologous booster response following two dose or single dose priming. Vaccine 30(43), 6127-6135 (2012).
45. Committee for Human Medicinal Products. Guideline on Dossier Structure and Content for Pandemic Influenza Vaccine Marketing Authorisation Application. Report No.: EMEA/CPMP/VEG/4717/2003-Rev.1. European Medicines Agency, London, UK (2008).
46. Fritz R, Sabarth N, Kiermayr S et al. A vero cell-derived whole-virus H5N1 vaccine effectively induces neuraminidase-inhibiting antibodies. J. Infect. Dis. 205(1), 28-34 (2012).
47. Crowe BA, Brühl P, Gerencer M et al. Evaluation of the cellular immune responses induced by a non-adjuvanted inactivated whole virus A/H5N1/VN/1203 pandemic influenza vaccine in humans. Vaccine 29(2), 166-173 (2010).
48. Galli G, Medini D, Borgogni E et al. Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc. Natl Acad. Sci. USA 106(10), 3877-3882 (2009).
49. Pedersen GK, Madhun AS, Breakwell L et al. T-helper 1 cells elicited by H5N1 vaccination predict seroprotection. J. Infect. Dis. 206(2), 158-166 (2012).
50. Kistner O, Crowe BA, Wodal W et al. A whole virus pandemic influenza H1N1 vaccine is highly immunogenic and protective in active immunization and passive protection mouse models. PLoS ONE 5(2), e9349 (2010).
51. Loew-Baselli A, Pavlova BG, Fritsch S et al. A non-adjuvanted whole-virus H1N1 pandemic vaccine is well tolerated and highly immunogenic in children and adolescents and induces substantial immunological memory. Vaccine 30(41), 5956-5966 (2012).
52. Ehrlich HJ, Müller M, Kollaritsch H et al. Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine. Vaccine 30(30), 4543-4551 (2012).
53. Twenty-second pandemic pharmacovigilance update. European Medicines Agency, 2010. Report No.: EMA/527985/2010.
54. Labrosse B, Tourdjman M, Porcher R et al. Detection of extensive cross-neutralization between pandemic and seasonal A/H1N1 Influenza Viruses using a pseudotype neutralization assay. PLoS ONE 5(6), e11036 (2010).
55. Lemaitre M, Leruez-Ville M, De Lamballerie XN et al. Seasonal H1N1 2007 influenza virus infection is associated with elevated pre-exposure antibody titers to the pandemic influenza A (H1N1) virus. Clin. Microbiol. Infect. 17(5), 732-737 (2011).
56. Parkman PD, Hopps HE, Rastogi SC, Meyer HM Jr. Summary of clinical trials of influenza virus vaccines in adults. J. Infect. Dis. 136, S722-S730 (1977). (Pubitemid 8286955)
57. Lagler H, Grabmeier-Pfistershammer K, Touzeau-Romer V et al. Immunogenicity and tolerability after two doses of non-adjuvanted, whole-virion pandemic influenza A (H1N1) vaccine in HIV-infected individuals. PLoS ONE 7(5), e36773 (2012).
58. Lagler H, Tobudic S, Ramharter M et al. Pandemic whole-virion, Vero-cell-derived, adjuvant-free influenza A H1N1 vaccine in patients with solid tumors and hematologic malignancies receiving concurrent anticancer treatment: Immunogenicity, tolerability, and acceptability during the pandemic situation. Vaccine 30(48), 6864-6870 (2012).
59. Lagler H, Wenisch JM, Tobudic S et al. Pandemic influenza A H1N1 vaccine in recipients of solid organ transplants: immunogenicity and tolerability outcomes after vero cell derived, non-adjuvanted, whole-virion vaccination. Vaccine 29(40), 6888-6893 (2011).
60. Nicholson KG, Abrams KR, Batham S et al. Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial. Lancet Infect. Dis. 11(2), 91-101 (2011).
61. Waddington CS, Walker WT, Oeser C et al. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. BMJ 340, c2649 (2010).
62. Palache AM, Brands R, van Scharrenburg GJ. Immunogenicity and reactogenicity of influenza subunit vaccines produced in MDCK cells or fertilized chicken eggs. J. Infect. Dis. 176(Suppl. 1), S20-S23 (1997). (Pubitemid 27315341)
63. Vesikari T, Block SL, Guerra F et al. Immunogenicity, safety and reactogenicity of a mammalian cell-culture-derived influenza vaccine in healthy children and adolescents three to seventeen years of age. Pediatr. Infect. Dis. J. 31(5), 494-500 (2012).
64. Ohmit SE, Petrie JG, Cross RT, Johnson E, Monto AS. Influenza hemagglutinationinhibition antibody titer as a correlate of vaccine-induced protection. J. Infect. Dis. 204(12), 1879-1885 (2011).
65. Fusaro A, Monne I, Salviato A et al. Phylogeography and evolutionary history of reassortant H9N2 viruses with potential human health implications. J. Virol. 85(16), 8413-8421 (2011).
66. Matrosovich MN, Krauss S, Webster RG. H9N2 influenza A viruses from poultry in Asia have human virus-like receptor specificity. Virology 281(2), 156-162 (2001). (Pubitemid 32881133)
67. Sorrell EM, Wan H, Araya Y, Song H, Perez DR. Minimal molecular constraints for respiratory droplet transmission of an avian-human H9N2 influenza A virus. Proc. Natl Acad. Sci. USA 106(18), 7565-7570 (2009).
68. Sun Y, Qin K, Wang J et al. High genetic compatibility and increased pathogenicity of reassortants derived from avian H9N2 and pandemic H1N1/2009 influenza viruses. Proc. Natl Acad. Sci. USA 108(10), 4164-4169 (2011).
69. Wan H, Sorrell EM, Song H et al. Replication and transmission of H9N2 influenza viruses in ferrets: evaluation of pandemic potential. PLoS ONE 3(8), e2923 (2008).
70. Wodal W, Falkner FG, Kerschbaum A et al. A cell culture-derived whole-virus H9N2 vaccine induces high titer antibodies against hemagglutinin and neuraminidase and protects mice from severe lung pathology and weight loss after challenge with a highly virulent H9N2 isolate. Vaccine 30(31), 4625-4631 (2012).
71. Romanova J, Krenn BM, Wolschek M et al. Preclinical evaluation of a replicationdeficient intranasal DeltaNS1 H5N1 influenza vaccine. PLoS ONE 4(6), e5984 (2009).
72. Centers for Disease Control and Prevention. Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP) -United States, 2012-13 Influenza Season. MMWR Morb. Mortal. Wkly Rep. 61, 613-618 (2012).
73. Mayrhofer J, Coulibaly S, Hessel A et al. Nonreplicating vaccinia virus vectors expressing the H5 influenza virus hemagglutinin produced in modified Vero cells induce robust protection. J. Virol. 83(10), 5192-5203 (2009).
74. Wu CY, Yeh YC, Yang YC et al. Mammalian expression of virus-like particles for advanced mimicry of authentic influenza virus. PLoS ONE 53, e9784 (2010).
75. WHO. Cumulative Number of Confirmed Human Cases of Avian Influenza A/ (H5N1) Reported to WHO. www.who.int/entity/influenza/human-animal- interface/H5N1-cumulative-table- archives/en/index.html
76. WHO. Pandemic (H1N1) 2009 -update 81. www.who.int/csr/don/2009-10-30/en/ index.html
77. US FDA. Guidance for Industry: Clinical Data Needed to Support the Licensure of Seasonal Inactivated Influenza Vaccines. www.fda.gov/downloads/ BiologicsBlood-Vaccines/GuidanceComplianceRegulatory-Information/Guidances/ Vaccines/ ucm091990.pdf
78. EMA. Pandemic Influenza Vaccine H5N1 Baxter AG: EPAR summary for the public. www.ema.europa.eu/docs/en-GB/ document-library/EPAR-Summary- for-the-public/human/001200/ WC500049617.pdf
79. EMA. Vepacel Influenza vaccine (whole virion, inactivated): EPAR summary for the public. www.ema.europa.eu/docs/en-GB/ document-library/EPAR-Summary- for-the-public/human/002089/ WC500124226.pdf
80. US FDA. Vaccines approved products: Flucelvax. www.fda.gov/ BiologicsBloodVaccines/ Vaccines/ApprovedProducts/ucm328629. htm
81. EMA. Optaflu influenza vaccine (surface antigen, inactivated, prepared in cell cultures): EPAR summary for the public. www.ema.europa.eu/docs/en-GB/ document-library/EPAR-Summary- for-the-public/human/000758/ WC500046952.pdf
82. The Legal Information System of the Republic of Austria, Austrian Federal Chancellory. 237. Verordnung der Bundesministerin für Arbeit, Gesundheit und Soziales über den Schutz der Arbeitnehmer/ innen gegen Gefährdung durch biologische Arbeitsstoffe (Verordnung biologische Arbeitsstoffe -VbA). www.ris.bka.gv.at/GeltendeFassung.wxe?A bfrage=Bundesnormen&Gesetzesnumm er=10009126
83. The European Parliament and the Council of the European Union. Directive 2000/54/EC of the European Parliament and of the Council of 18 September 2000 on the protection of workers from risks related to exposure to biological agents at work (seventh individual directive within the meaning of Article 16(1) of Directive 89/391/EEC). http://eur-lex.europa.eu/LexUriServ/ LexUriServ.do?uri= OJ:L:2000:262:0021: 0045:EN:PDF
84. WHO. WHO Technical Report Series No 941, 2007 Annex 5: WHO biosafety risk assessment and guidelines for the production and quality control of human influenza pandemic vaccines. www.who.int/biologicals/publications/trs/ areas/vaccines/influenza/Annex%205%20 human%20pandemic%20influenza.pdf
85. WHO. Updated unified nomenclature system for the highly pathogenic H5N1 avian influenza viruses. www.who.int/influenza/gisrs-lab oratory/ h5n1-nomenclature/en/index.html#
86. CDC. Additional information about vaccination of specific populations. www.cdc.gov/flu/professionals/acip/ specificpopulations.htm
87. European Centre for Disease Prevention and Control. Guidance: priority risk groups for influenza vaccination. http://ecdc.europa.eu/en/publications/ Publications/0808-GUI-Priority-Risk- Groups-for-Influenza-Vaccination.pdf
88. CDC. Chronic disease prevention and health promotion. www.cdc.gov/chronicdisease/overview/ index.htm
89. EMA. Celvapan influenza vaccine (H1N1) v (whole virion, Vero cell derived, inactivated). EPAR summary for the public. www.ema.europa.eu/docs/en- GB/ document-library/EPAR-Summary- for-the-public/human/000982/ WC500022671.pdf
90. EMA. CHMP Recommendations for the pharmacovigilance plan as part of the risk management plan to be submitted with the marketing authorisation application for a pandemic influenza vaccine. www.ema.europa.eu/docs/en-GB/ document-library/Report/2010/01/ WC500051739.pdf
91. WHO. Antigenic and genetic characteristics of A(H5N1), A(H7N3), A(H9N2) and variant influenza viruses and candidate vaccine viruses developed for potential use in human vaccines. www.who.int/influenza/vaccines/virus/ characteristics-virus-vaccines/en/index. html